Compare Oscar Health Inc (OSCR) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oscar Health Inc vs Xylem, Inc. — how do they compare? Oscar Health Inc trades at $33.4 (market cap $10.22B), while Xylem, Inc. trades at $103 (market cap $23.81B). The key difference: Xylem, Inc. is far larger — about 2.3× Oscar Health Inc's market cap, and Xylem, Inc. pays a 1.69% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oscar Health Inc for 15 Days and Xylem, Inc. for 50 Days on average.
| OSCR | XYL | |
|---|---|---|
Market Cap | $10.22B | $23.81B |
Volume | 4,123,394 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $33.81 | $152.95 |
52-Week Low | $10.85 | $100.92 |
Typical Hold Time | 15 Days | 50 Days |
Enterprise Value | $6.57B | $25.59B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OSCR trades at $33.37, up 1.4% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B in 2026, turning profitable with $551M net income. Recent Q1 and Q2 2026 earnings beat expectations, while analyst consensus leans toward Hold (61.54%) with a $34 price target. Technical indicators show bullish signals but RSI suggests potential overbought conditions near-term.
Outlook remains positive with scalable ACA market growth and margin expansion driving earnings potential. Key risks include rising medical costs threatening profitability and competitive pressures. The stock offers growth exposure but requires monitoring of execution on 2029 EPS targets of $4+ and medical loss ratio management.
XYL trades at $102.71, up 0.86% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $9.04B in 2025 with a net income margin of 10.59%, and has beaten EPS estimates in recent quarters. Recent developments include a $1.5B senior note offering to fund acquisitions of Cornell Pump and Roper Pump, and the appointment of a new CFO.
Outlook is supported by strong water-solutions demand and margin expansion, but risks include China weakness and higher debt. Analysts are mixed with a consensus price target of $149.13, implying significant upside from current levels, though near-term technical pressure may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
